Clyde Biosciences is a leading global cardiac safety service provider. Our speciality is in the assessment of cardiotoxicity potential for the global pharmaceutical industry. We work with:
Our technology was developed in the laboratory of Professor Godfrey Smith (Chief Scientific Officer, Clyde Biosciences) a world-leading cardiac scientist with 25+ years experience in cardiac electrophysiology research. Clyde’s CellOPTIQ® platform delivers reliable, high resolution functional output from a range of cardiac cell types including iPS-derived heart cells. High bandwidth membrane voltage signals from CellOPTIQ® provides new insights into electrophysiological effects of drugs. Rapid data capture and analysis is made possible by our bespoke software which allows accelerated assay throughput in a 96 well format.
In vitro cardiotox using iPS cardiomyocytes on a voltage sensitive dye platform. Voltage, calcium and contraction studies. Capable of running more straight forward CiPA assays through to complex mechanistic tox studies using chronic protocols. Study design and interpretation performed by Prof Smith (CSO) and data presented at a high standard for IND submission.
Clyde Biosciences is an official member of the CiPA consortium, and a Core Group member contributing towards the development of the next generation of assays.
We run drug screening studies on our CellOPTIQ® system using the accepted CiPA Protocol. Only Clyde can provide you with a rapid-turnaround VSD screening study on your compounds.
Clyde works with virtually all of the major suppliers of iPS-CMs to characterise their cells on using the standard CiPA protocol. These data provide an invaluable reference point for the performance of cells. CellOPTIQ® works with 2D and 3D structures.
Major benefits include:
Clyde Biosciences works with the leading manufacturers of iPS-CMs to provide a broad dataset of parameters, enabling companies to understand the performance of their cells in the context of drug testing.
These data are essential for iPS-CM suppliers to communicate accurately the characteristics of their cells to biopharma companies.
Clyde is able to provide our clients with access to the highest quality ion channel screening technology
Clyde’s Ion Channel Service:
The Rational Approach
hiPSC-CM - Human induced pluripotent stem cell-derived cardiomyocytes
Clyde Biosciences Ltd. has not received any reviews.
Clyde Biosciences Ltd. has not received any endorsements.